Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPPORT: CPAP vs Surfactant and Oxygen Targets in Preterm Infants
NCT00233324Phase 3Completed
- Sponsor
- NICHD Neonatal Research Network
- Start
- Feb 2005
- Primary completion
- Feb 2009
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxygen in respiratory distress syndrome (RDS), retinopathy of prematurity (ROP) and bronchopulmonary dysplasia (BPD) (4 arms), sponsored by NICHD Neonatal Research Network. Primary endpoints: Survival Without Bronchopulmonary Dysplasia at 36 weeks and Survival Without Severe Retinopathy of Prematurity at 55 weeks. Started Feb 2005; status: completed.
02
Drugs
oxygen
03
Conditions
respiratory distress syndrome (RDS)retinopathy of prematurity (ROP)bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT00233324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00233324.